FIBROGEN INC Business Operations Contracts & Agreements
27 Contracts & Agreements
- Administration Agreements (1 contract)
- Collaboration Agreements (3)
- Development Agreements (17)
- Services Agreements (1)
- Supply Agreements (5)
- Amendment No. 4 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of October... (Filed With SEC on February 28, 2022)
- Amendment No. 3 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of January... (Filed With SEC on May 10, 2021)
- Astellas EU Supply Agreement by and between FibroGen, Inc. and Astellas Pharma Europe Ltd, effective as of January 1, 2021 (Filed With SEC on May 10, 2021)
- Master Services Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020 (Filed With SEC on March 1, 2021)
- Collaboration Agreement by and between FibroGen, Inc. and Astellas Pharma Inc., effective June 1, 2005 (Filed With SEC on November 5, 2020)
- Amendment No. 1 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective as of May... (Filed With SEC on August 6, 2020)
- Commercial Supply Agreement by and between FibroGen, Inc. and Catalent Pharma Solutions, LLC, effective as of January 1, 2020 (Filed With SEC on March 2, 2020)
- Amendment No. 33 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of January... (Filed With SEC on May 9, 2019)
- Amendment No. 1 to Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of January 1, 2013 (Filed With SEC on February 27, 2019)
- Work Order No. 1 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of... (Filed With SEC on February 27, 2018)
- Amendment No. 32 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of... (Filed With SEC on February 27, 2018)
- Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of June 1, 2005 (Filed With SEC on November 8, 2017)
- State-Owned Construction Land Use Right Granting Contract Promulgated by Ministry of Land and Resources of the Peoples Republic of China State Administration for Industry and... (Filed With SEC on May 9, 2017)
- Amendment No. 31 to the Process Development and Clinical Supply Agreement (Filed With SEC on May 9, 2017)
- Amendment No. 30 to the Process Development and Clinical Supply Agreement (Filed With SEC on March 1, 2017)
- Amendment No. 29 to the Process Development and Clinical Supply Agreement (Filed With SEC on March 1, 2017)
- Amendment No. 26 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)
- Amendment No. 25 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)
- Amendment No. 24 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)
- Amendment No. 22 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)
- AMENDMENT NO. 23 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO. 21 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO. 20 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO.19 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO.17 TOTHE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO. 16 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
- AMENDMENT NO. 15 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)
